Paquet K J, Feussner H
Hepatology. 1985 Jul-Aug;5(4):580-3. doi: 10.1002/hep.1840050409.
A prospective randomized controlled clinical trial was performed in 43 consecutive histologically proved cirrhotic patients with endoscopically proved actively bleeding esophageal varices. Twenty-two were randomly selected to have esophageal tamponade with the Sengstaken-Blakemore tube, and 21 were selected to have endoscopic sclerosis of the esophageal wall. The two groups were similar in demographic, clinical and laboratory data. Bleeding was controlled by the Sengstaken-Blakemore tube in 16 of 22 patients (73%) and by endoscopic sclerosis in 20 of 21 (95%). Among those controlled by the Sengstaken-Blakemore tube, seven (44%) rebled and three (43%) were again controlled by the Sengstaken-Blakemore tube; in the endoscopic sclerosis group, four (20%) rebled and three (75%) were controlled. Thus, hemorrhage was definitively controlled in 52% of patients and 66% of bleeding episodes in the Sengstaken-Blakemore tube group and in 90% of patients and 92% of bleeding episodes in the endoscopic sclerosis group. The definite control of hemorrhage was significantly better in the endoscopic sclerosis group (p less than 0.01). The Sengstaken-Blakemore tube patients received no definitive therapy after bleeding had been controlled. Within 30 days, six patients (27%) in the Sengstaken-Blakemore tube group had died compared to 2 (10%) in the endoscopic sclerosis group which is statistically significant (p less than 0.01) in favor of endoscopic sclerosis. The frequency of complications was similar in the two groups. Endoscopic sclerosis patients received serial endoscopic sclerosis after bleeding had been stopped during the whole period of follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)
对43例经组织学证实为肝硬化且经内镜证实有活动性出血的食管静脉曲张患者进行了一项前瞻性随机对照临床试验。随机选择22例患者使用Sengstaken - Blakemore管进行食管压迫止血,21例患者接受食管壁内镜硬化治疗。两组在人口统计学、临床和实验室数据方面相似。22例使用Sengstaken - Blakemore管的患者中,16例(73%)出血得到控制;21例接受内镜硬化治疗的患者中,20例(95%)出血得到控制。在使用Sengstaken - Blakemore管控制出血的患者中,7例(44%)再次出血,其中3例(43%)再次使用Sengstaken - Blakemore管控制出血;在内镜硬化治疗组中,4例(20%)再次出血,其中3例(75%)出血得到控制。因此,Sengstaken - Blakemore管组52%的患者和66%的出血发作得到了明确控制,内镜硬化治疗组90%的患者和92%的出血发作得到了明确控制。内镜硬化治疗组在出血明确控制方面明显更好(p小于0.01)。出血得到控制后,使用Sengstaken - Blakemore管的患者未接受确定性治疗。30天内,Sengstaken - Blakemore管组有6例患者(27%)死亡,而内镜硬化治疗组有2例患者(10%)死亡,这在统计学上有显著差异(p小于0.01),支持内镜硬化治疗。两组并发症发生率相似。内镜硬化治疗的患者在整个随访期间出血停止后接受了系列内镜硬化治疗。(摘要截短至250字)